Status:
RECRUITING
The International SubcutaneouS Implantable Cardioverter Defibrillator Registry (iSuSI)
Lead Sponsor:
University of Luebeck
Collaborating Sponsors:
Prof. Jürgen Kuschyk, M.D
Giovanni Forleo, M.D.
Conditions:
Sudden Cardiac Death
Eligibility:
All Genders
18-99 years
Brief Summary
The entirely subcutaneous implantable defibrillator (S-ICD) (Emblem, Boston Scientific, Marlborough, MA, USA) was introduced as a new therapeutic alternative to the conventional transvenous ICD in 200...
Detailed Description
The S-ICD has a CE mark and is FDA approved since 2012 and is mentioned as a potential therapy strategy in the current AHA guidelines on the management of patients with ventricular arrhythmias.2 Howev...
Eligibility Criteria
Inclusion
- Implantation of an S-ICD, regardless of the technique
- At least 1 month of follow up
- At least 1 post-implantation assessment, in accordance to the routine clinical practice of every center (e.g. in person visit or remote follow up)
Exclusion
- \- none
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT05390047
Start Date
July 1 2022
End Date
September 30 2025
Last Update
July 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinic for Rhythmology
Lübeck, Schleswig-Holstein, Germany, 23538